Series
Most Recent Segment
KOL Connect
Featuring AIM Immuno
May 14, 2026
Professor Doctor Casper H.J. van Eijck, MD, PhD, Professor and Pancreato-biliary Surgeon at Erasmus Medical Center (“Erasmus MC”) and a consultant for AIM, and AIM Chief Executive Officer Thomas K. Equels, MS, JD, participate in a Virtual Investor KOL Connect segment.
Prof. Dr. van Eijck, a globally recognized pancreatic cancer clinical expert and the foremost expert in the use of Ampligen in pancreatic cancer, examines Ampligen’s mechanism of action, its potential to provide a positive immunotherapeutic approach, existing clinical data, development strategy, and anticipated regulatory milestones, supporting AIM’s focused commitment to advancing a potential new treatment option for patients with late-stage pancreatic cancer.
What This Means
What This Means provides investors with context to press releases directly from company management teams. It also provides the opportunity for companies to communicate directly to investors and elaborate on recent key news and highlight value driving milestones.
CEO Connect
CEO Connect allows investors to hear directly from company CEOs, who will provide a brief presentation followed by an interactive Q&A session. Investors and interested parties have the opportunity to submit questions live during the event.
KOL Connect
KOL Connect features a moderated, in-depth discussion with members of the management team from participating companies along with Key Opinion Leaders.
What This Means
Featuring enVVeno Medical
May 12, 2026
Robert Berman, Chief Executive Officer of enVVeno Medical, discusses the Company’s recent news announcing the U.S. Food and Drug Administration’s (FDA) first-ever IDE approval awarded to enVVeno to proceed with a U.S. pivotal study of a non-surgical replacement venous valve.
KOL Connect
Featuring Ernexa Therapeutics
May 11, 2026
Dr. Robert Pierce, Chief Scientific Office for Ernexa, provides insight into the complexities of ovarian cancer, highlights the patient journey from diagnosis through treatment, and emphasizes the persistent unmet need for more effective and durable treatment options.
Dr. Pierce also outlines the evolving treatment landscape and shares his perspective on how Ernexa is approaching ovarian cancer differently at the biological level. He discusses the Company’s lead product candidate, ERNA101, and its potential to improve outcomes and enhance the patient experience compared to existing therapies.
What This Means
Featuring Akari Therapeutics
April 9, 2026
Abizer Gaslightwala, CEO of Akari Therapeutics, discusses the Company’s strategic partnership with WuXi XDC and its implications for platform validation and development acceleration, highlighting accelerated IND timeline for AKTX-101 and positioning within the rapidly evolving ADC landscape.
What This Means
Featuring Daré Bioscience
March 12, 2026
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses the significance of the FDA’s IND clearance and how this milestone allows Daré to advance DARE-HPV into Phase 2 clinical development in alignment with Daré’s broader strategy to address unmet needs in women’s health.
What This Means
Featuring GRI Bio
February 17, 2026
Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI Bio, discussed important insights from the Company’s recently reported additional positive Phase 2a data in Idiopathic Pulmonary Fibrosis (IPF), including a series of compelling biomarker results that demonstrate improvements in key drivers of fibrosis and lung repair.
What This Means
Featuring Akari Therapeutics
February 11, 2026
Abizer Gaslightwala, CEO of Akari Therapeutics, discussed Akari’s recently announced patent filing and the introduction of AKTX-102, the Company’s second ADC pipeline candidate targeting CEACAM5-expressing solid tumors.
What This Means
Featuring Decoy Therapeutics
February 4, 2026
Peter Marschel, Chief Business Officer of Decoy, discusses how the Company’s “design-for-manufacturing” approach supports the rapid transition of peptide-conjugate therapeutics from laboratory development to commercial-scale production and is designed to enable a distributed global manufacturing network capable of responding to emerging viral threats. The platform will be validated using Decoy’s intranasal pan-coronavirus fusion inhibitor, which is funded under the same Gates Foundation grant.
What This Means
Featuring Ernexa Therapeutics
February 3, 2026
Sanjeev Luther, President & CEO of Ernexa, highlighs how regulatory alignment from the FDA on Ernexa’s development strategy for its lead cell therapy, ERNA-101, provides a clear pathway toward submitting an Investigational New Drug application and initiating clinical testing in the second half of 2026.
CEO Connect
Featuring SENTI Bio
January 14, 2026
Timothy Lu, MD, PhD, CEO of Senti, discusses its recent news release announcing that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the Company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, that is currently in development for the treatment of relapsed/refractory hematologic malignancies, including AML.
CEO Corner
Featuring Autonomix
December 23, 2025
Brad Hauser, CEO of Autonomix, outlines two key priorities shaping the Company’s trajectory: strengthening its platform through intellectual property protection and evaluating opportunities beyond pancreatic cancer, including potential applications in cardiovascular, pulmonary and interventional pain management areas.